Latest progress and challenges in drug development for degenerative motor neuron diseases

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Motor neuron diseases (MNDs) are fatal neurodegenerative conditions affecting motor neurons.
• Amyotrophic lateral sclerosis (ALS) is a representative MND, with variants differing mainly in lesion location.
• Pathogenesis theories include gene mutation, excitotoxicity, autoimmunity, and neurotrophic factors.

Purpose of the Study:

• To provide a comprehensive overview of drug research trends and treatment prospects for MNDs, focusing on ALS.
• To summarize recent clinical trials and preclinical findings in motor neuron disease drug development.
• To highlight the latest potentialities for clinical therapy in ALS and related disorders.

Main Methods:

• Review of clinical trials completed between January 1, 2023, and June 30, 2024, sourced from clinicaltrials.gov.
• Analysis of ongoing trials across Phase I, II, and III, with a focus on disease-modifying therapies.
• Inclusion of promising preclinical candidates like ATH-1105.

Main Results:

• 24 clinical trials are investigating potential disease-modifying therapy drugs for ALS.
• Current trials include 5 in Phase I, 17 in Phase II, and 11 in Phase III.
• FDA-approved drugs include riluzole, edaravone, and tofersen; AMX0035 was withdrawn.

Conclusions:

• Significant research efforts are directed towards disease-modifying therapies for ALS.
• Ongoing clinical trials represent diverse approaches to treating motor neuron diseases.
• Despite challenges, emerging therapies show promise for improving clinical outcomes in MNDs.